Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia
NCT ID: NCT05192304
Last Updated: 2022-01-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
62 participants
INTERVENTIONAL
2022-02-01
2024-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Phase I Study of HS-10509 in Chinese Adult Subjects
NCT06301074
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
NCT03652974
A Clinical Trial to Evaluate Safety, Tolerance and Pharmacokinetics of JX11502MA Capsule in Patients With Schizophrenia.
NCT06356389
Multiple Dose Safety Study of PF-04802540 in Subjects With Schizophrenia
NCT00876304
Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia
NCT00063297
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
0.2mg single dose
single dose of TPN-672 0.2mg, 2 subjects
TPN-672
single dose of TPN-672 maleate tablet
0.3mg single dose
single dose of TPN-672 0.3mg, 12 subjects（9 for TPN-672, 3 for placebo）
TPN-672
single dose of TPN-672 maleate tablet
0.4mg single dose
single dose of TPN-672 0.4mg, 12 subjects（9 for TPN-672, 3 for placebo）
TPN-672
single dose of TPN-672 maleate tablet
0.5mg single dose
single dose of TPN-672 0.5mg, 12 subjects（9 for TPN-672, 3 for placebo）
TPN-672
single dose of TPN-672 maleate tablet
0.6mg single dose
single dose of TPN-672 0.6mg, 12 subjects（9 for TPN-672, 3 for placebo）
TPN-672
single dose of TPN-672 maleate tablet
0.7mg single dose
single dose of TPN-672 0.7mg, 12 subjects（9 for TPN-672, 3 for placebo）
TPN-672
single dose of TPN-672 maleate tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TPN-672
single dose of TPN-672 maleate tablet
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. 18.5kg/m2 ≤ body mass index (BMI) ≤ 30kg/m2, and weight ≥ 50kg for men and ≥ 45kg for women.
3. Subjects met DSM-5 diagnostic criteria for a confirmed diagnosis of schizophrenia and were stable within the past 6 months as assessed by the investigator.
4. Subjects are currently taking aripiprazole, olanzapine or risperidone monotherapy for schizophrenia at a dose not exceeding the maximum dose specified in the instructions and the dose and frequency of administration have not changed in the last 1 month.
5. Screening period PANSS scale total score \<70, PANSS scale individual score of positive symptom items ≤3, CGI-S score ≤4.
6. Individual scores were ≤1 on the SAS scale, ≤2 on the AIMS scale, and ≤2 on item 4 of the BARS scale, "Overall clinical assessment of sedentary inability" during the screening period.
7. Female and male subjects of childbearing potential and their spouses must be able to secure effective contraception (medically approved contraception such as IUDs, the pill or condoms) during the study and for 6 months after the end of the drug administration.
8. Subjects and their guardians fully understand the purpose and requirements of the trial, voluntarily participate in the clinical trial and sign a written informed consent form, and are willing to complete the entire trial process according to the trial requirements.
Exclusion Criteria
2. Subjects were administered strong inducers/strong inhibitors of CYP2D6, CYP3A4, CYP3A5, CYP2C9 for 5 half-lives prior to the first dose.
3. Subjects were on long-acting antipsychotics for 6 months prior to their first dose.
4. Received electroconvulsive therapy, transcranial magnetic stimulation (rTMS) within 1 month prior to screening
5. Those who answered "yes" to questions 4 or 5 of the suicidal ideation entry on the Columbia Suicide Scale (C-SSRS) during the screening period, or who were currently or within the past 12 months significantly suicidal, or who were considered to be at risk for suicidal and violent behavior based on the investigator's clinical assessment.
6. Those with abnormal physical examination or vital signs during the screening period that are clinically significant.
7. Abnormal laboratory tests during the screening period that the investigator determines to be clinically significant, e.g., liver: ALT or AST≥ 1.2 times the upper limit of normal; kidney: Cr\> the upper limit of normal value.
8. Prolactin ≥ 5 times the upper limit of normal during the screening period.
9. Screening subjects with systolic blood pressure \<90 mmHg or \>140 mmHg and diastolic blood pressure \< 60mmHg or \>90mmHg.
10. Patients with poorly controlled diabetes (fasting glucose ≥ 10 mmol/L), or are On insulin for diabetes, or at screening with a primary diagnosis of type 2 diabetes.
11. Screening QTc interval \>450ms (men) or 470ms (women), or family history of long QT interval syndrome, or combined cardiac insufficiency, severe arrhythmia or ischemic heart disease requiring medication, congenital heart disease, severe organic heart disease or history of such disease.
12. Combined with convulsive disorders such as epilepsy (except febrile convulsions)
13. Current or previous hyper- or hypothyroidism, Parkinson's disease, malignancy.
14. Tobacco addiction within 1 year prior to screening, with an average of \>10 cigarettes or equivalent per day.
15. Alcohol consumption within 1 year prior to screening, with an average weekly intake of more than 14 units of alcohol (1 unit = 285 ml of beer or 25 ml of spirits or 150 ml of wine) or a positive breath test for alcohol.
16. Persons with a history of drug or substance abuse within 1 year prior to screening or a positive urine drug screen.
17. Subjects who may be hypersensitive to any of the components of this drug.
18. HIV antibody, HBsAg, HCV antibody or positive syphilis serology results.
19. History of significant blood loss or blood loss ≥ 200 ml in the 3 months prior to screening
20. Enrolled in another clinical trial within 3 months prior to screening, or currently participating in a clinical trial.
21. Women who are expecting or breastfeeding.
22. The investigator did not consider it appropriate to participate in this trial.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Mental Health Center
OTHER
Jiangsu Kanion Pharmaceutical Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Li Huafang, MD PhD
Role: PRINCIPAL_INVESTIGATOR
Shanghai Mental Health Center
Li Guanjun
Role: PRINCIPAL_INVESTIGATOR
Shanghai Mental Health Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BR-2020-1491-TPN672
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.